Provided by Tiger Fintech (Singapore) Pte. Ltd.

Revolution Medicines, Inc.

40.67
-0.8000-1.93%
Post-market: 40.56-0.1100-0.27%19:15 EDT
Volume:3.04M
Turnover:123.67M
Market Cap:7.56B
PE:-11.37
High:41.72
Open:41.31
Low:40.20
Close:41.47
Loading ...

Positive Clinical Data and Competitive Efficacy Drive Buy Rating for Revolution Medicines’ Zoldonrasib

TIPRANKS
·
Yesterday

Why Is Cancer Drug Developer Revolution Medicines Stock Trading Higher On Monday?

Benzinga
·
28 Apr

S&P 500 Futures Drop In Premarket Trading; McCormick Vtg, TPG Lag

Dow Jones
·
28 Apr

Barclays Keeps Their Buy Rating on Revolution Medicines (RVMD)

TIPRANKS
·
28 Apr

Revolution Medicines Presents Initial Data From Zoldonrasib (Rmc-9805) Study in Patients With Kras G12d Mutant Non-Small Cell Lung Cancer at the 2025 Aacr Annual Meeting

THOMSON REUTERS
·
28 Apr

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD), UnitedHealth (UNH) and Edwards Lifesciences (EW)

TIPRANKS
·
21 Apr

Revolution Medicines Price Target Maintained With a $59.00/Share by Needham

Dow Jones
·
08 Apr

Small to Mid-Cap Biotechnology Firms Likely to Continue to Face Macro Headwinds, BofA Securities Says

MT Newswires Live
·
03 Apr

Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

GlobeNewswire
·
02 Apr

Revolution Medicines Inc : Stifel Cuts Target Price to $64 From $78

THOMSON REUTERS
·
01 Apr

Revolution Medicines to Participate in April 2025 Investor Conferences

GlobeNewswire
·
01 Apr

Is Revolution Medicines (RVMD) the Best Mid Cap Biotech Stock to Buy?

Insider Monkey
·
31 Mar

Revolution Medicines Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
03 Mar

Revolution Medicines, Inc. : H.c. Wainwright Raises Target Price to $73 From $72

THOMSON REUTERS
·
03 Mar

Revolution Medicines’ Earnings Call: Positive Progress Amid Rising Costs

TIPRANKS
·
28 Feb

Analysts Conflicted on These Healthcare Names: Revolution Medicines (RVMD) and Genmab (GMAB)

TIPRANKS
·
27 Feb

Revolution Medicines Is Maintained at Buy by Needham

Dow Jones
·
27 Feb

Q4 2024 Revolution Medicines Inc Earnings Call

Thomson Reuters StreetEvents
·
27 Feb

Stifel Nicolaus Reaffirms Their Buy Rating on Revolution Medicines (RVMD)

TIPRANKS
·
27 Feb

Analysts Are Bullish on Top Healthcare Stocks: Amneal Pharmaceuticals (AMRX), Revolution Medicines (RVMD)

TIPRANKS
·
27 Feb